Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New ligands for L-type Ca2+ channels.

D Rampe1, D J Triggle

  • 1Merrell Dow Research Institute, Cincinnati, OH 45215.

Trends in Pharmacological Sciences
|March 1, 1990
PubMed
Summary

New drugs targeting voltage-dependent calcium channels may offer better treatments. These novel agents act at additional sites, potentially improving therapeutic effects and reducing side effects compared to existing medications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Overview of chemical diversity.

Current protocols in pharmacology·2011
Same author

Addiction.

IDrugs : the investigational drugs journal·2005
Same author

Division of Medicinal Chemistry--integrins: past, present and future.

IDrugs : the investigational drugs journal·2005
Same author

Effects of the atrial antiarrhythmic drug AVE0118 on cardiac ion channels.

Naunyn-Schmiedeberg's archives of pharmacology·2004
Same author

Development and evaluation of high throughput functional assay methods for HERG potassium channel.

Journal of biomolecular screening·2001
Same author

Interactions of the antimalarial drug mefloquine with the human cardiac potassium channels KvLQT1/minK and HERG.

The Journal of pharmacology and experimental therapeutics·2001

Area of Science:

  • Pharmacology
  • Molecular Biology
  • Cardiovascular Research

Background:

  • Clinically significant drugs like verapamil, nifedipine, and diltiazem target L-class voltage-dependent calcium channels at distinct sites.
  • Existing drug classes are understood to interact with three primary binding sites on these channels.

Purpose of the Study:

  • To explore the actions of novel drug classes modulating voltage-dependent calcium channel activity.
  • To investigate potential new therapeutic and side-effect profiles of these emerging agents.
  • To gain further insights into the structure and function of L-class calcium channels.

Main Methods:

  • The study describes the actions of newly identified drug classes.
  • Analysis of drug interactions at potential additional sites on L-class calcium channels.
  • Comparison of novel agents with existing calcium channel blockers.

Main Results:

  • New drug classes modulate voltage-dependent calcium channel activity through mechanisms potentially distinct from established drugs.
  • These novel agents may exhibit improved therapeutic efficacy and reduced adverse effects.
  • Evidence suggests interaction at additional sites beyond the three known major sites.

Conclusions:

  • Novel calcium channel modulators offer promise for improved therapeutic outcomes and side-effect profiles.
  • These drugs provide valuable tools for further defining the structure-function relationships of L-class calcium channels.
  • Endogenous ligands mimicking these drugs' actions could guide future calcium channel drug design.

Related Experiment Videos